Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | VP, Research & Development | August 15, 2023 | August 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protalix BioTherapeutics, Inc.
Report date August 15, 2023 · Filed August 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 35,115 |
Reported balance
After 2023-08-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-08-15 · Grant · Acquired 35,115 · Balance 35,115 F1: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended (the "Plan"). The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.99 · Expires 2033-08-15 | Direct | 35,115 |
Reported balance
After 2023-08-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-15 · Grant · Acquired 35,115 · Balance 35,115 F3: The shares of common stock underlying the stock options vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F4: Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030 and options to purchase 250,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 9, 2032. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended (the "Plan"). The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
F2: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.
F3: The shares of common stock underlying the stock options vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.
F4: Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030 and options to purchase 250,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 9, 2032.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2023 Filed Aug 17, 2023 20:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 35,115 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001104659-23-093069 · tm2324046-2_4seq1.xml · derivative · entry 2 Hayon Yael · CIK 0001817121 · VP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,115 Underlying: Common Stock · 35,115 shares Expires 2033-08-15 F3 · derivative.exercise_date: The shares of common stock underlying the stock options vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F4 · balance_after: Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030 and options to purchase 250,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 9, 2032. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 35,115 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-093069 · tm2324046-2_4seq1.xml · nonDerivative · entry 1 Hayon Yael · CIK 0001817121 · VP, Research & Development 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 35,115 F1 · price: Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended (the "Plan"). The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 21:03 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-22-098951 · tm2225460-8_4seq1.xml · derivative · entry 1 Hayon Yael · CIK 0001817121 · VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-09-07 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include options to purchase 129,771 shares of common stock at an exercise price equal to $3.73 per share that expire on July 5, 2030. Read SEC document |
| July 05, 2020 Filed Jul 8, 2020 21:01 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 129,771 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001104659-20-082116 · tm2024387d2_4.xml · derivative · entry 1 Hayon Yael · CIK 0001817121 · VP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,771 Underlying: Common Stock · 129,771 shares Expires 2030-07-05 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.